AI Article Synopsis
- Behavioral phenotyping in neonatal mice helps researchers study how early changes in brain development relate to human neurodevelopmental disorders.
- This chapter outlines a testing method that assesses mice behavior while reducing stress for the pups and their mothers.
- Testing starts when mice are 6-8 days old and includes various evaluations up to 20-21 days, focusing on different behavioral traits like movement and reflexes.
Article Abstract
Behavioral phenotyping approaches for neonatal mice are important for investigating early alterations in brain development and function, relevant to neurodevelopmental disorders in humans. This chapter describes a behavioral screen that can provide an overall profile of function across the neonatal and preweaning period while also minimizing pup stress and disturbance of the maternal environment. Testing begins when mice are between 6 and 8 days in age, with additional evaluations at discrete time points until postnatal day (PD) 20-21, using tests for negative geotaxis, surface righting reflex, activity in an open field, acoustic startle responses and sensorimotor gating, and limb clasp.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/978-1-0716-2752-5_14 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ofatumumab treatment in new-onset narcolepsy type 1 following SARS-CoV-2 infection.
Ann Clin Transl Neurol
December 2024
Department of Neurology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Objectives: To explore the efficacy of ofatumumab in new onset narcolepsy type 1 following SARS-CoV-2 infection.
Methods: We present a 9-year-old girl who experienced new onset narcolepsy type 1 following SARS-CoV-2 infection. Polysomnography (PSG) followed by a daytime multiple sleep latency test (MSLT) was under taken after admission.
Patient-Reported Experience Measures for In- and Outpatients in Mental Health and Substance Use Services: Psychometric Properties and Results From a Nationwide Survey in Finland.
Int J Methods Psychiatr Res
March 2025
Mental Health, Health Care and Social Welfare, Finnish Institute for Health and Welfare (THL), Helsinki, Finland.
Objectives: We implemented the first national patient experience survey, with novel patient-reported experience measures (PREMs), in out- and inpatient mental health and substance use services in Finland.
Methods: The Outpatient Experience Scale (OPES) and the Inpatient Experience Scale (IPES) were co-designed with experts by experience and professionals. The survey was carried out in 2021 in 435 treatment facilities.
A Case of NTRK Fusion Corpus Sarcoma With Pseudobiphasic Growth Pattern and Literature Review.
Int J Gynecol Pathol
December 2024
Department of Pathology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, P.R. China.
The incidence of neurotrophic tyrosine kinase receptor (NTRK) fusion uterine sarcoma is extremely low, and reports have been mostly focused on cases localized to the cervix. So far, only 4 cases have been reported of the uterine corpus. In this study, we reported a case of NTRK fusion corpus sarcoma.
View Article and Find Full Text PDFAvoidant Restrictive Food Intake Disorder in Pediatric Liver Transplant Patients.
Pediatr Transplant
February 2025
Department of Surgery, University of California, San Francisco, California, USA.
Introduction: Following liver transplantation (LT), adequate nutrition is essential, as malnutrition may contribute to slower growth in pediatric patients and put patients at risk of complications following transplant. Avoidant Restrictive Food Intake Disorder (ARFID) is an eating disorder characterized by restrictive eating patterns that compromise nutrition. Patients with ARFID may have significant difficulty meeting nutritional needs due to fear of gastrointestinal distress, making it especially difficult to manage in patients following LT.
View Article and Find Full Text PDFMyelofibrosis (MF) is a myeloproliferative neoplasm that was most commonly treated with hydroxyurea (HU) prior to approval of ruxolitinib (RUX), now the standard of care. Factors that influence changes in MF treatment in real-world settings are not well understood. The METER study (NCT05444972) was a multi-country retrospective chart review of MF treatment patterns, treatment effectiveness, and healthcare resource utilization.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!